Patent Grant
11214625
A computer readable text file, entitled “SequenceListing.txt” created on or about Jul. 17, 2020 with a file size of about 66 kb contains the sequence listing for this application and is hereby incorporated by reference in its entirety.
The invention belongs to the field of biopharmaceutical technology, including the role and mechanism of PCSK9 in inflammatory immune diseases and the application of PCSK9 inhibitors in the preparation of drugs for treating inflammatory immune diseases.
The incidence of inflammatory immune diseases is high, and there are at least hundreds of millions of people worldwide, including many autoimmune diseases, such as psoriasis, eczema (atopic dermatitis), lupus erythematosus, rheumatoid arthritis, dermatomyositis, scleroderma, Crohn's Disease, etc.). Because these diseases can involve multiple organs, leading to organ injury of heart, liver, kidney, blood vessel, lung, joint and brain. Its mortality rate is second only to malignant tumor. In view of the fact that the etiology and pathogenesis of these diseases is quite complex and cannot be cured at present. Glucocorticoids and immunosuppressants are the main therapeutic drugs commonly used in clinical practice. The effective rate of these drugs is only about 50%. And the severe adverse side effect, which include bone marrow suppression, liver and kidney dysfunction, osteoporosis, susceptibility to infection and tumors, greatly limit long-term use of such drugs. In recent years, the biologics have gradually become the popular direction of drug research and development due to the selectivity of the therapeutic targets and the little side effects. But so far, only a few of these biologic drugs have achieved great efficacy. At the same time, high prices limit wide application.
Proprotein convertase subtilisin kexin 9 (PCSK9) is a member of the proprotein convertase family, which is secreted as an inactive proenzyme in the liver. The cDNA of the PCSK9 gene is 3617 bp, which encodes a PCSK9 protein with 692 amino acids. The PCSK9 precursor separated N-terminal predomain by intramolecular catalyzing, then the separated N-terminal anterior region is connected to catalytic region to allow mature PCSK9 proteins to leave the endoplasmic reticulum and enter the secretory pathway. After PCSK9 is secreted into the extracellular space, it binds at the cell surface to the low density lipoprotein (LDL) receptor in the first epidermal growth factor like domain. Following binding, PCSK9-LDL binding receptor complex enters lysosome to degrade, which leads to the decrease of LDL receptors on the cell surface. Therefore, the level of PCSK9 is negatively correlated with the level of LDL receptor. Several studies have shown that the mutation of PCSK9 gene can significantly decrease the LDL cholesterol level and the incidence of coronary heart disease in different patient groups.
In view of the significant effect of inhibition of PCSK9 on reducing LDL cholesterol and coronary disease, a number of treatment schemes have been developed to deactivate PCSK9, for the purpose of reducing LDL cholesterol and coronary disease. Because of its high efficiency, target selectivity, and good stability, monoclonal antibodies have become a hot spot in new drug research. Two PCSK9 monoclonal antibodies have recently been approved by FDA and the European Medicines Agency (EMA) for treating hypercholesterolemia in patients who are still unable to reduce LDL by current treatments.
The PCSK9 monoclonal antibodies that have been launched to treat hypercholesterolemia include Alirocumab (SAR236553/REGN727, Sanofi & Regeneron Pharma) and Evolocumab (AMG 145, Amgen). Preclinical trials of other PCSK9 monoclonal antibodies, such as Pfizer's Bococizumab (as RN316/PF 04950615) and LY3015014 (Eli Lilly and Company), have been completed. Overall, the clinical research found that the patients with hypercholesterolemia treated with these drugs had good tolerance, and there was no significant difference in the incidence of adverse reactions between the placebo group and the active treatment group.
The main target for inhibition of PCSK9 secretion is mRNAs, which can be obtained by using antisense oligonucleotides (ASOS) to obtain their short sequences, which can be given intravenously in the form of small lipid nanoparticles. In rats, liver-specific siRNA targeting PCSK9 could make the maximum silencing efficiency at 50-60%. The plasma LDL cholesterol level decreased by 30%. In non-human primates, a dose of 5 mg drug reduced LDL cholesterol by 56-70% after 72 hours and lasted for 3 weeks. In phase I trial, the siRNA oligonucleotide ALN-PCS02 was investigated. Compared with placebo, the drug can quickly reduce the level of PCSK9 (average 68%) and LDL cholesterol (average 41%) in a dose-dependent manner. The drug is safe and has no obvious adverse effects.
For PCSK9 small molecule inhibitors, Pfizer is developing a PCSK9 small molecule inhibitor. In animal experiments, the drug can significantly reduce LDL cholesterol level. In addition, the company is designing a vaccine drug that patients need only once a year to achieve a long-term reduction in LDL.
However, so far, all new research and drug development projects related to PCSK9 inhibitors have been based on their role in reducing LDL cholesterol level and coronary disease. So far, there has been no reporting on the use of PCSK9 inhibitors in the treatment of inflammatory and immune diseases.
It is well known that the incidence of inflammatory immune diseases is high; their pathogenesis is complex and they include many diseases. However, there are often similar etiological or pathological bases among different inflammatory immune diseases. They are usually treated with the same drugs: glucocorticoids and immunosuppressants, which are used most frequently in clinical practice. For the development of new drugs, the high degree of similarity in the treatment and medication of various types of inflammatory immune diseases. so a disease model that is easy to observe and analyze the outcome of the treatment is usually chosen to carry out the preliminary study. At present, because the therapeutic effect of psoriatic lesions is easy to observe, it has become the experimental field to generally study the treatment of inflammatory immune diseases. Psoriasis is an immunological disease mediated by T cells with multiple genetic mutation background. It is susceptible to be associated with metabolic syndrome (hypertension, hyperlipidemia, hyperglycemia and obesity) and cardiovascular disease. The disease is prone to relapse and requires lifelong treatment. Psoriasis mainly includes four types: psoriasis vulgaris, psoriasis pustulose, psoriasis erythematosus, and psoriasis arthritis. According to the severity it is divided into mild, moderate, severe. At present, immunosuppressants and retinoic acid are commonly used in the treatment of severe psoriasis. Adverse reactions are common, including bone marrow suppression, liver and kidney injury and hyperlipidemia. Psoriatic Arthritis (PsA) is the second most common inflammatory joint disease, which can lead to disability. Compared with rheumatoid arthritis (RA), PsA lacks appropriate treatment drugs. Antirheumatic drugs for improving the condition of the disease such as Methotrexate, leflunomide and other antirheumatics, which lack randomized experimental evidence, have been the first line PsA treatment. With the research progress on the pathogenesis of the disease, biological agents, which are the key targets of the pathogenesis of the disease have been gradually used in clinical treatment. At present, biological agents used in the treatment of psoriasis and PsA mainly include monoclonal antibodies (mAbs) against TNF-α, a target of immune pathogenesis pathway. They include inflexim monoclonal antibody (trade name: Remicade), adamumab injection (trade name: Merlot), human recombinant II tumor necrosis factor receptor antibody fusion protein for injection (trade name: Etanercept), and Ulinumab, which targets IL-12 and IL-23 common subunit P40. However, about 30% of patients may show poor or ineffective response to these drugs, and long-term use also carries the risk of inducing infection (including tuberculosis) and tumors. Both the European Drug Agency (EMA) and the Food and Drug Administration (FDA) found that there seemed to be no better treatment for those who don't respond to the currently available drug. In conclusion, none of the currently available drugs can effectively improve metabolic disorders in psoriatic patients. So far, no therapeutic target has been found to treat psoriatic lesions and metabolic abnormalities.
The problems to be solved in the present invention: the role and mechanism of PCSK9 in the treatment of inflammatory immune diseases and the application of PCSK9 inhibitors in the preparation of drugs for the treatment of inflammatory immune diseases. The invention uses psoriasis as an example for the study of inflammatory immune diseases, and finds that PCSK9 plays an important role in the treatment of a variety of inflammatory immune diseases.
We first found that PCSK9 plays an important role in the treatment of a variety of inflammatory immune diseases. We used PCSK9 knockout transgenic mice to establish psoriatic like inflammatory model induced by imiquimod, which proves that inhibition of PCSK9 has a very obvious therapeutic effect on psoriatic inflammatory lesions. A study on the mechanism of inhibiting PCSK9 in the treatment of inflammatory immune diseases by cultured human keratinocytes found that knock-down of PCSK9 expression by siRNA could significantly inhibit the abnormal proliferation of keratinocyte and promote its apoptosis through NFkb pathway.
To further confirm the role of PCSK9 in the pathogenesis of psoriasis, the invention collected lesions and non-lesions from 30 psoriasis patients, and skin samples from 30 normal human subjects. The immunohistochemistry results showed: the expression of PCSK9 in psoriatic lesions was significantly higher than that in non-lesions and normal controls (p<0.05). PCSK9 positive cells were mainly distributed in epidermis and dermis near the epidermis, but not in dermis vessels. Detected by real-time fluorescence quantitative nucleic acid amplification detection system (Q-PCR), it was found that the expression of PCSK9 was found in the skin of both patients and normal subjects, but it was significantly higher in the psoriasis patients than in the normal controls (P<0.01). No expression of PCSK9 was found in the peripheral blood mononuclear cells (PBMC) of patients with psoriasis, eczema, and urticaria and the control group by Q-PCR. However, the expression of PCSK9 in blood in patients with psoriasis, eczema and urticaria was significantly higher than that in the control group by ELISA (P<0.05).
Next, we isolated CD4 T cells from peripheral blood of patients with active psoriasis, eczema and urticaria and found PCSK9 protein could significantly promote the secretion of IL-17, IL-2 and IFN-Gamma by CD4 T cells, and increased the expression of NFkb, especially in psoriatic patients.
In all PCSK9 inhibitors, representative monoclonal antibodies, small interfering RNA and small molecular inhibitors were selected herein. Treated psoriasis-like mice model by subcutaneous injection (the dose is the same as the known LDL cholesterol experiment) in comparison with control group. The results showed that the therapeutic effect of PCSK9 monoclonal antibody group and PCSK9 small molecule inhibitor group was significantly better than that of control group. There were no obvious adverse reactions in PCSK9 monoclonal antibody group and PCSK9 small molecule inhibitor group. The results showed that the systemic use of PCSK9 small molecule inhibitors and PCSK9 monoclonal antibodies had obvious therapeutic effects on psoriasis-like inflammation and the therapeutic effect was significantly better than that of the control group.
In some embodiments, representative PCSK9 small molecule inhibitors and PCSK9 monoclonal antibodies were prepared for use as an external ointment (drug concentration 0.001-0.05%) and applied to IMQ induced inflammatory psoriasis like lesions in mice once a day in comparison with external ointment without drugs as controls. The results showed that the efficacy of PCSK9 monoclonal antibody group and PCSK9 small molecule inhibitor group was significantly better than that of control group. The effect of PCSK9 small molecule inhibitor group was better than that of PCSK9 monoclonal antibody group, and there was no obvious adverse reaction in each group. It was proved that topical use of PCSK9 small molecule inhibitor and PCSK9 monoclonal antibody had obvious therapeutic effect on psoriasis-like inflammation and their efficacy was better than that of control group.
In some embodiments, representative PCSK9 small molecule interference RNA (siPCSK9) was applied to IMQ induced psoriasis like inflammatory lesions in mice, once a day. Compared with the control group, the lesions of the siPCSK9 group were improved obviously, and no obvious adverse reaction was found.
For the first time, it was found that: 1. Both systemic and topical use of PCSK9 monoclonal antibody, PCSK9 small molecule inhibitor, and siPCSK9 have therapeutic effects on psoriatic lesions, which are significantly superior to those of the control group. In some embodiments, the invention relates to the treatment of psoriatic lesion by a PCSK9 inhibitor selected from the group consisting of representative PCSK9 monoclonal antibody, PCSK9 small molecule inhibitor and siPCSK9.
Because of its high inhibiting efficiency, selectivity and good efficacy, monoclonal antibody has been widely used in the research of new drugs. Our study also found that, small molecular inhibitors and small interfering RNA aimed at PCSK9 were more effective than monoclonal antibodies in the treatment of psoriasis-like inflammation. Generally, monoclonal antibodies have fewer side effects than small molecular inhibitors, and are more stable than small interfering RNA preparations. However, according to our data, small molecular PCSK9 inhibitors and siPCSK9 not only have a good efficacy in the treatment of psoriasis like inflammation, but also have mild side effects.
It is well known to one skilled in this field that, based on the above mechanism of PCSK9, PCSK9 inhibitors have therapeutic effect on other T cell mediated chronic immune diseases. These include, but are not limited to, psoriasis, psoriatic arthritis, eczema (atopic dermatitis), urticaria, glucocorticoid dependent dermatitis, rheumatoid arthritis, scleroderma, diabetes, chronic liver disease and lymphoma, etc. In some embodiments, the invention relates to the treatment of a T-cell medicated chronic immune disease, wherein the T-cell medicated chronic immune disease is selected from psoriasis, psoriatic arthritis, eczema (atopic dermatitis), urticaria, glucocorticoid dependent dermatitis, rheumatoid arthritis, scleroderma, diabetes, chronic liver disease, and lymphoma; wherein the PCSK9 inhibitor is a PCSK9 small molecule inhibitor, a PCSK9 monoclonal antibody or a siPCSK9; wherein the PCSK9 inhibitor can be used alone or in combination with other therapeutic agents, including traditional drugs and other new biological agents.
In some embodiments, PCSK9 inhibitor comprising the PCSK9 monoclonal antibody, PCSK9 small molecule interfered RNA and PCSK9 small molecule inhibitors are used for treating psoriasis, atopic dermatitis or urticaria. In some embodiment, the PCSK9 inhibitor was applied topically on the skin.
In an embodiment, the invention relates to a method of treating psoriasis by topical use of a PCSK9 inhibitor, wherein the PCSK9 inhibitor is selected from the group consisting of a PCSK9 monoclonal antibody, a siPCSK9 and a PCSK9 small molecule inhibitor. In an embodiment, the PCSK9 inhibitor is a PCSK9 vaccine.
In an embodiment, the inhibition of PCSK9 expression by siPCSK9 can significantly inhibit the abnormal proliferation of human keratinocytes and promote their apoptosis through NFkb pathway. In an embodiment, the invention relates to a method of treating keratinocytes by the use of siPCSK9.
In an embodiment, the PCSK9 small molecule inhibitor is selected from the group consisting of
In an embodiment, the PCSK9 small molecule inhibitor is selected from the compounds listed in Table 1. The patent application number cited in Table 1 are incorporated by reference in their entirety.
In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody selected from the group consisting of Alirocumab, Evolocumab, Bococizumab, DS-001, CA-001, MS-001, LY3015014, NS-001, and antigen binding fragments, variants, conjugates or biosimilars thereof.
In an embodiment, the PCSK9 inhibitor is Alirocumab or antigen binding fragments, variants, conjugates or biosimilars thereof. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising SEQ ID NO:1 and SEQ ID NO:2. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 99% identical to SEQ ID NO:1 and SEQ ID NO:2. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 95% identical to SEQ ID NO:1 and SEQ ID NO:2. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 90% identical to SEQ ID NO:1 and SEQ ID NO:2.
In an embodiment, the PCSK9 inhibitor is Evolocumab or antigen binding fragments, variants, conjugates or biosimilars thereof. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 99% identical to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 95% identical to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 90% identical to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.
In an embodiment, the PCSK9 inhibitor is Bococizumab or antigen binding fragments, variants, conjugates or biosimilars thereof. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 99% identical to SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 95% identical to SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 90% identical to SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15.
In an embodiment, the PCSK9 inhibitor is DS-001 or antigen binding fragments, variants, conjugates or biosimilars thereof. In an embodiment, DS-001 is a PCSK9 antibody comprising SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 99% identical to SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 95% identical to SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 90% identical to SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.
In an embodiment, the PCSK9 inhibitor is CA-001 or antigen binding fragments, variants, conjugates or biosimilars thereof. In an embodiment, CA-001 is a PCSK9 antibody comprising SEQ ID NO:20, and SEQ ID NO:21. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 99% identical to SEQ ID NO:20, and SEQ ID NO:21. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 95% identical to SEQ ID NO:20, and SEQ ID NO:21. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 90% identical to SEQ ID NO:20, and SEQ ID NO:21.
In an embodiment, the PCSK9 inhibitor is MS-001 or antigen binding fragments, variants, conjugates or biosimilars thereof. In an embodiment, MS-001 is a PCSK9 antibody comprising SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 99% identical to SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 95% identical to SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 90% identical to SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33.
In an embodiment, the PCSK9 inhibitor is LY3015014 or antigen binding fragments, variants, conjugates or biosimilars thereof. In an embodiment, LY3015014 is a PCSK9 antibody comprising SEQ ID NO:34 and SEQ ID NO:35. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 99% identical to SEQ ID NO:34 and SEQ ID NO:35. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 95% identical to SEQ ID NO:34 and SEQ ID NO:35. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 90% identical to SEQ ID NO:34 and SEQ ID NO:35.
In an embodiment, the PCSK9 inhibitor is NS-001 or antigen binding fragments, variants, conjugates or biosimilars thereof. In an embodiment, NS-001 is a PCSK9 antibody comprising SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, and SEQ ID NO:41. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 99% identical to SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, and SEQ ID NO:41. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 95% identical to SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, and SEQ ID NO:41. In an embodiment, the PCSK9 inhibitor is a PCSK9 antibody comprising sequences at least 90% identical to SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, and SEQ ID NO:41.
The invention provides a new and better treatment method for the treatment of inflammatory immune diseases. Through the disclosure of the invention, the system or topical PCSK9 inhibitor can be further prepared, and a new monomer drug or compound preparation containing various PCSK9 inhibitors can be developed. Furthermore, new monomers or compound formulations containing all kinds of PCSK9 inhibitors have been developed for the treatment of various types of inflammatory immune diseases, especially psoriasis, eczema and urticaria. Clinical trials have shown that these drugs, which contain PCSK9 inhibitors, are effective, have little adverse reactions, and are well tolerated in patients. In particular, topical use alone can significantly improve lesions in immune diseases such as psoriasis. It is very suitable for the current clinical demand and is expected to have great application prospect, which will bring more advantages to the patients with inflammatory and immunological diseases.
The following specific examples illustrate the embodiments of this invention. Technical personnel in this field can easily understand the other advantages and effects of the invention from the contents disclosed in this invention. The invention is not limited to the embodiments described herein. Before further describing the embodiments of this invention, it should be understood that the scope of protection of the invention is not limited to the following specific embodiment. It should be also understood that the term used in the specific examples of the invention is used to describe a specific embodiment rather than to limit the protection scope of the invention. In the description and claims of the invention, unless expressly stated in the text, the singular form “one” and “this” include plural forms.
It should be understood that when a numerical range is given in an example, unless stated by the invention, the two endpoints and any between the two endpoints of each numerical range can be selected. Unless defined herein, all technical and scientific terms used in the invention have the same meaning as those commonly understood by those in the technical field. Except for specific methods, equipment, materials used in the embodiment, according to the description of the invention, one skilled in the art would understand the use of the equivalents of the methods, equipment, and materials described herein.
PCSK9 Knockout Significantly Alleviates Psoriasis-Like Inflammation Reaction Induced by IMQ in Mice
Reagents: 5% imiquimod cream (IMQ), PCSK9 antibody (abcam), NF-kB antibody(abcam)
Experimental animal: C57BL/6 (B6) mice, 7 male; C57BL/6-PCSK9-r-mice, 5 males and 5 females. The mice were purchased at the Jackson Institute in Maine, USA (The Jackson Laboratory).
Experimental Methods:
1. After two groups of mice with different genotypes were treated with back hair removal, 5% Imiquimod cream of 62.5 mg was applied daily for 5 days.
2. Scores (the score of erythema, scales, skin lesions thickening and total score) were taken and archived (the score was obtained by two researchers respectively then average score was calculated) before and after the application.
3. On the last day of the experiment, all the mice were eulogized and the skin tissue of the back (treated and untreated) was taken.
4. The morphology of skin lesions in each group was observed by HE staining and the expression and distribution of PCSK9 and NF-kB in skin lesions of 4 groups were measured by immunofluorescence method.
Experimental Results:
1. After 5 days of continuous application, there were obvious erythema, scales and infiltration in the back of 7 C57BL/6 mice, which were in accordance with the appearance of psoriasis-like skin lesions. In 10 PCSK9 knockout mice, there were only slight erythema, scales and infiltration in the back coating area (See
2. A daily score was given on the skin lesions of the drug-coated area on the back of the mice, the score of erythema, scale, infiltration and total score of C57BL/6 mice were significantly higher than those of PCSK9 knockout mice (P<0.05).
3. After 5 days of application, the skin tissues of the mice's back (treated and untreated) were taken for HE staining and pathological changes were observed. The skin of IMQ treatment area of C57BL/6 mice showed typical psoriasis pathological changes, such as skin thickening, dermatoid lengthening, thickening of spinous layer, hyperkeratosis with incomplete keratosis, Kogoj abscess and Munro abscess, etc. However, the skin of PCSK9 gene knockout mice showed mild epidermis thickening and hyperkeratosis, no typical pathological changes of psoriasis, such as extension of dermatoid, thickening of spinous layer, hyperkeratosis with incomplete keratosis, Kogoj abscess and Munro abscess. The untreated skin of both groups showed normal skin structure (see
Transfection of Si-PCSK9 Enhances Apoptosis and Inhibits Proliferation of Human Keratinocytes.
Experimental Materials and Reagents:
Experimental Methods:
1. Cultured human keratinocytes were replanted in 6 wells plates. When the cell density was 60-70%, si-RNA (si-Con and siPCSK9) transfection was carried out. After 24 h/48 h/72 h of transfection, measured the cell activity of each pore by MTT method. 3 wells were selected at each time point for each group, the average value was taken and the cell activity curve was plotted.
2. Cultured human keratinocytes were replanted in 6 wells plates. When the cell density was 60-70%, si-RNA (si-Con & si-PCSK9) transfection was carried out. After 24 h/48 h/72 h of transfection, cells were harvested respectively for AnnexinV and PI staining to detect cell apoptosis and cell cycle. 3 wells were selected at each time point for each group, the average value was taken.
Experimental Results:
1. The number of survival cells of human primary keratinocytes transfected with si-PCSK9 was significantly lower than that of si-Con transfection (P<0.05, See
2. The apoptosis of primary keratinocytes transfected with si-PCSK9 was significantly higher than that of si-Con transfection (P<0.05), while proliferating (the proportion of S+G2/M phase cells) decreased significantly (see
The Expression of PCSK9 in Psoriatic Lesions was Significantly Higher than that in Non-Lesions and Normal Controls.
Experiment materials: lesions and non-lesion from 30 psoriasis patients, skin samples from 30 normal people were treated with PCSK9 antibody (abcam).
Methods: immunohistochemistry, real time quantitative-PCR.
Results: the skin of patients with skin lesions and non-lesions was extracted by drilling method. The skin of normal people originated from the redundant skin of cosmetic surgery. The results of immunohistochemistry showed that the expression of PCSK9 in psoriatic lesions was significantly higher than that in non-lesions and normal controls. PCSK9 positive cells were mainly distributed in epidermis and dermis near epidermis, but not in dermis vessels (see
Expression of PCSK9 in Peripheral Blood Mononuclear Cells and Plasma in Patients with Psoriasis, Eczema and Urticaria.
Materials: 5 ml peripheral blood from 30 cases of psoriasis, 30 cases of eczema, 30 cases of urticaria, and 30 cases of normal persons was collected respectively.
Empirical Method:
(1) Separation of plasma and separation of peripheral PBMC by density gradient method.
(2) Detection of PCSK9 expression in PBMC by real-time quantitative Q-PCR.
(3) The expression of PCSK9 in plasma was detected by enzyme linked immunosorbent assay (Elisa) (PCSK9 Quantikine ELISA Kit, America R&D)
(4) Results: (1) No PCSK expression was detected in PBMC of the samples of psoriasis, eczema, urticarial and normal people.
(5) PCSK expression in the samples of psoriasis, eczema, and urticaria are much higher than that in the sample of the normal people. PCSK expression is the highest in the samples of psoriasis.
Effect of PCSK9 Protein on the Secretion of IL-17 and IL-2 from Peripheral CD4+T Cells in Patients with Psoriasis, Eczema or Urticaria.
Materials: peripheral blood of 10 cases of psoriasis, 10 cases of eczema, 10 cases of urticaria, and 10 cases of normal people. ELISA kit was purchased from Raybiotech
Company of USA.
Experimental Methods:
(1) Isolation of CD4+T cells from peripheral blood:
After PBMC was isolated by Ficoll-Hypaque from human peripheral blood by density gradient centrifugation, washed with 10 times volume 1×BD beads buffer. Then 50 ul BD IMag TM CD4 beads were added to each 107 cells. The beads were mixed well and incubated at room temperature for 30 minutes. 1 ml 1×BD magnetic bead buffer solution was added, and the cells were transferred to the round bottom tube and placed in the magnetic frame for 8 to 10 minutes. And then the supernatant was discarded and removed the test tube from the magnetic field. After resuspension of cells attached to tube wall with 1 ml 1×BD magnetic bead buffer, the tubes were placed in magnetic field for 2-4 min again. The supernatant was discarded removed it out of the magnetic field, resuspended the cells and placed the tube in the magnetic field for 2-4 min. The cells obtained from the supernatant can be used in subsequent experiments. BD IMag TM CD4 separation system was purchased from BD Biosciences Company.
(2) Determination of cytokines secreted by CD4+T cells in Peripheral Blood
The supernatant was collected after cell culture under different conditions. IFN-Gamma represented TH1 type cytokines, IL-4 represented TH2 type cytokines, and IL-17 represented TH17 cytokines. The detection of IFN-Gamma, IL-4, IL-17 was conducted by ELISA.
Results: Compared to the normal patients, PCSK9 protein can significantly promote the secretion of IL-17, IL-2 and IFN-Gamma (P<0.01) by CD4 T cells isolated from peripheral blood of patients with psoriasis, eczema and urticaria (
Subcutaneous Injection of PCSK9 Small Molecule Inhibitor and PCSK9 Monoclonal Antibody Significantly Alleviated Systemic Immune Abnormalities and Skin Lesions Induced by IMQ in Mice. The Efficacy of PCSK9 Small Molecule Inhibitor is Better than that of Subcutaneous Injection of PCSK9 Monoclonal Antibody.
Reagents:
The PCSK9 small molecule inhibitor used for this example has the formula of:
The PCSK9 monoclonal antibody used for this example is Evolocumab. 40 SPF female BALB/c mice aged 6-8 weeks were randomly divided into normal control group, model group, PCSK9 small molecule inhibitor group and PCSK9 monoclonal antibody group. There were 10 mice for each group. After intraperitoneal injection of pentobarbital sodium 80 mg/kg, the back was shaved with an area of about 2 cm×3 cm. The mice were feed separately for 1 day.
(1) In normal control group, Vaseline was applied locally. In model group, inhibitor group and monoclonal antibody group, 62.5 mg of 5% imiquimod cream was applied on the back every day for 6 consecutive days, photos were taken and the PASI score was evaluated.
(2) On the first day, normal saline was subcutaneously administrated to normal control group and model group, PCSK9 small molecule inhibitor was subcutaneously administrated (8 mg/kg, Purchased from Selleck Inc.) to inhibitor group, and PCSK9 monoclonal antibody was subcutaneously administrated to monoclonal antibody group (10 mg/kg, Purchased from abcam Inc.)
Experimental Results:
(1) After 6 days of continuous application, there were marked erythema, scales and infiltration in the back of the mice in the model group. However, in PCSK9 small molecule inhibitor group and PCSK9 monoclonal antibody group, there was only mild erythema, scales and infiltration in the back coating area of mice. The effect of PCSK9 small molecule inhibitor group was better than that of PCSK9 monoclonal antibody group. No lesions were observed in the vaseline group (
(2) A daily scoring was given on the skin lesions of the drug-coated area on the back of the mice. The score of erythema, scales, infiltration and total score of PCSK9 small molecule inhibitor group (erythema+scales+infiltration) were significantly lower than that of PCSK9 monoclonal antibody group (P<0.01).
Both PCSK9 Small Molecule Inhibitor and PCSK9 Monoclonal Antibody Improved the IMQ Induced Psoriatic Lesions of Mice, and the Efficacy of Small Molecule Inhibitor was Better than that of Monoclonal Antibody
Reagents:
The PCSK9 small molecule inhibitor used for this example has the formula of:
The PCSK9 monoclonal antibody used for this example is Evolocumab.
(1) 40 SPF female BALB/c mice aged 6-8 weeks were randomly divided into normal control group, model group, PCSK9 inhibitor group and PCSK9 monoclonal antibody group. There were 10 mice for each group. After intraperitoneal injection of pentobarbital sodium 80 mg/kg, the back was shaved with an area of about 2 cm×3 cm. The mice were feed separately for 1 day.
(2) In normal control group, vaseline was applied locally. In model group, small molecule inhibitor group and monoclonal antibody group, 62.5 mg of 5% imiquimod cream was applied on the back every day for 6 consecutive days, and photos were taken and the PASI score was evaluated.
(3) Pretreatment: vaseline was applied on the back skin with mics in normal control group and model group, PCSK9 small molecule inhibitor cream (0.01% concentration) was applied to inhibitor group once daily. And, PCSK9 monoclonal antibody cream (0.01% concentration) was applied to monoclonal antibody group once daily.
(4) After 7 days pretreatment, vaseline was applied on the back skin with mice in normal control group. At the same time, 62.5 mg 5% imiquimod cream was regularly applied daily on the back with mice in model group, small molecule inhibitor group and monoclonal antibody group. PCSK9 small molecule inhibitor cream or PCSK9 monoclonal antibody cream was applied after one hour. For 6 consecutive days, photos were taken and the PASI score was evaluated.
Experimental Results:
1. After 6 days of continuous administration, erythema, scales and infiltration were observed in the coating areas at the back of the mics in the model group. However, there were only slight erythema, scales and infiltration in the back of the mice in the PCSK9 small molecule inhibitor group and the PCSK9 monoclonal antibody group. The effect of PCSK9 small molecule inhibitor group was better than that of PCSK9 monoclonal antibody group. No lesion was observed in the vaseline group (See
2. A daily score was given on the skin lesions of the drug-coated area on the back of the mice. The score of erythema, scales, infiltration and total score (erythema+scales+infiltration) in PCSK9 small molecule inhibitor group was significantly lower than that in PCSK9 monoclonal antibody group (P<0.01).
External Use of siRNA for PCSK9 could Significantly Reduce Psoriatic Lesions Induced by IMQ in Mice.
Materials and Methods:
1. Animal models: two types of mice models, C57BL/6J (B6) and Balb/cByJ (BALB) were used in this study. The mice was purchased at the Jackson Institute in Maine, USA. (The Jackson Laboratory). The strain number was 000664, 001026 and 005993 respectively (www.jax.org). All the mice in this experiment were female, aged 3-8 months, 5 mice for each group.
2. Psoriatic lesions induced by IMQ: the back hair of B 6 mice was removed one day before the experiment. During the experiment, 62.5 mg imiquimod (IMQ, 3 M pharmaceuticals) were smeared on the skin of each mouse with an area of 2 cm2 on the back. In some mice, right auricle was also smeared with 5 mg IMQ to detect skin thickening easily. After 24 hours, score of the skin color, thickness and scales degree was evaluated.
3. Inhibition of PCSK9 by siRNA and its effect on psoriatic lesions induced by IMQ: Two siRNAs for PCSK9 (siPCSK9-1, 2) and a random sequence siRNA (siCon), used as a control trial, was synthesized by Sigma-Aldrich company (Sigma-Aldrich, USA). The sequence was shown in Table 3. Mixed siPCSK9-1 and 2 equally and diluted it to 20 μM with normal saline. 12.5 μl diluted siPCSK9 was evenly mixed with 7.5 μl moisturizer (CVS Pharmacy, Baby Lotion), so it was done with siCon. Applied 20 μl siRNA-moisturizer mixture to the skin 1 hour before IMQ was applied. PCSK9 monoclonal antibody was purchased from abcam Company and was evenly mixed with PCSK9 moisturizer (CVS pharmacy, Baby Lotion) to generate an equal concentration emulsion with siPCSK9 emulsion.
4. From the first day, siCON was applied on the back skin of B6 mice in model group after 1 hour-vaseline treatment. B6 mice in siPCSK9 group were smeared with 5% imiquimod cream on their back, then 1 hour thereafter, siPCSK9 was applied once daily. In PCSK9 monoclonal antibody group, 5% imiquimod cream was applied on the back skin of B6 mice, then 1 hour thereafter, PCSK9 monoclonal antibody was applied once daily.
5. Gene expression detection by semi quantitative (real-time PCR): Primer sequence was shown in Table 3
Experimental Results:
1. siPCSK9 can significantly reduce the expression of PCSK9 in the skin of B6 mice one day after being applied to the skin (p<0.05); inhibition rate is over 80% (
2. After 6 days of continuous application, there were significant erythema, scales and infiltration in the coating area of the model group, but only slight erythema, scale and infiltration in the siPCSK9 group (see
3. Daily scoring of skin lesions in B6 mice showed that the scores of erythema, scale, infiltration and the total scores (erythema+scale+infiltration) in siPCSK9 group were significantly lower than those in control group (P<0.01) (
4. To further verify the inhibitory effect of siPCSK9 on psoriatic lesions induced by IMQ, we repeated the experiment in
The specific embodiments are described above in detail. Within the knowledge of the technical personnel in this field, various changes can also be made without departing from the concept of the invention.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201510728438.6 | Oct 2015 | CN | national |
| Number | Name | Date | Kind |
|---|---|---|---|
| 9227956 | Darout et al. | Jan 2016 | B2 |
| 10513514 | Wu | Dec 2019 | B2 |
| 20140315928 | Darout et al. | Oct 2014 | A1 |
| 20150374710 | Abdel-Meguid et al. | Dec 2015 | A1 |
| 20150376139 | Abdel-Meguid et al. | Dec 2015 | A1 |
| 20160058768 | Darout et al. | Mar 2016 | A1 |
| 20160256467 | Abdel-Meguid et al. | Sep 2016 | A1 |
| 20170290806 | Abou-Gharbia et al. | Oct 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 103717615 | Apr 2014 | CN |
| 105143203 | Dec 2015 | CN |
| 105214087 | Jan 2016 | CN |
| 0372776 | Jun 1990 | EP |
| 201400464 | Jan 2014 | TW |
| 2012177741 | Dec 2012 | WO |
| WO 2013137371 | Sep 2013 | WO |
| 2014150395 | Sep 2014 | WO |
| 2014170786 | Oct 2014 | WO |
| WO 2014170786 | Oct 2014 | WO |
| 2014197752 | Dec 2014 | WO |
| 2016107602 | Jul 2016 | WO |
| 2016107603 | Jul 2016 | WO |
| 2017034990 | Mar 2017 | WO |
| 2017034994 | Mar 2017 | WO |
| 2017034997 | Mar 2017 | WO |
| 2017071673 | May 2017 | WO |
| 2017222953 | Dec 2017 | WO |
| Entry |
|---|
| International Search Report for International Application No. PCT/CN2016/111613, dated Feb. 20, 2017 (translation). |
| Written Opinion of the International Searching Authority for International Application No. PCT/CN2016/111613, dated Feb. 20, 2017 (translation). |
| Mao, Chengyu et al., “Research progress on proprotein convertase subtilisin 9,” Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular Diseases, Issue 10, 2015, 191-194 (translated abstract). |
| Pan, Lihong et al., “PCSK9/Narc-1 and nervous system diseases,” Journal of Nanhua University (Medical Edition), Issue 6, 2008, 808-809 (translated abstract). |
| Number | Date | Country | |
|---|---|---|---|
| 20180312607 A1 | Nov 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/CN2016/111613 | Dec 2016 | US |
| Child | 15965907 | US |
